Iain Ross joined the Company as Executive Chairman on 9 September 2010. Mr Ross has over 35 years’ experience in the international life sciences and technology sectors where he has completed multiple financing transactions, and over 25 years in cross-border management as a Chairman and CEO. He has led and participated in five Initial Public Offerings, and has direct experience of M&A transactions in Europe, USA and Pacific Rim.
Currently he is Executive Chairman of e-Therapeutics plc (LSE: ETX) and non-Executive Chairman of Biomer Technology Ltd; and also a non-executive director of Anatara LifeSciences Ltd and Novogen Ltd, both of which are listed on the ASX. He is a qualified Chartered Director, and Vice Chairman of the Council of Royal Holloway, London University.
Previously, he has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, Reed Business Publishing and Celltech Group plc where, as CEO of Celltech Biologics plc, he moved the company from a loss-making position to reporting a net profit before the sale to Lonza. He has advised banks and private equity groups on numerous company turnarounds. These include as CEO of Quadrant Healthcare taking the company public, signing numerous collaborations and selling the business to Elan in 2001. As Chairman and CEO at Allergy Therapeutics he re-structured the company balance sheet to position Allergy Therapeutics as a virtually debt-free cash generative company prior to its subsequent IPO. As Executive Chairman at Silence Therapeutics Plc (formerly SR Pharma plc), he turned the business around through M&A and established collaborations with Pfizer, Astra Zeneca and Dainippon Sumitomo before completing a merger with Intradigm Inc. He continues to consult for private equity groups on biotech and technology company turnarounds.
On 31 March 2013, the permanent position of Executive Chairman was made redundant. Mr Ross was appointed as Non-Executive Chairman on 1 April 2013 and stepped down from that position on 25 April 2016, having overseen the successful reverse takeover of the Company into Ark Therapeutics Group plc in February 2015. Mr Ross remains on the Board as a non-executive director and is also a member of the Nomination, Audit and Remuneration Committees.